Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Becaplermin
Therapeutic Area : Podiatry
Study Phase : Approved FDF
Sponsor : Lynch Regenerative Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration
Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.
Product Name : Regranex
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 31, 2025
Lead Product(s) : Becaplermin
Therapeutic Area : Podiatry
Highest Development Status : Approved FDF
Sponsor : Lynch Regenerative Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Details : The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.
Product Name : Epidex
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase IV
Recipient : Henry Ford Health System
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Bioinductive Implant for Tennis Elbow (Lateral Epicondylitis)
Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Tennis Elbow.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 24, 2018
Lead Product(s) : Undisclosed
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase IV
Recipient : Henry Ford Health System
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers
Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pressure Ulcer.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 24, 2016
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Santyl Within an Accountable Care Organization
Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pressure Ulcer.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 23, 2016
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Podiatry
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Santyl in Diabetic Foot Ulcers
Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Collagenase Inhibitor
Therapeutic Area : Podiatry
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HP802-247
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Healthpoint
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
Details : HP802-247 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leg Ulcer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 03, 2012
Lead Product(s) : HP802-247
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Healthpoint
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
